Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Schizophrenia

AI Summary

Initiating OLZ/SAM was associated with significant and clinically meaningful reductions in inpatient admissions and emergency department visits versus baseline.
Average inpatient days per patient decreased significantly by approximately 5.2 to 5.5 days during the 12-month follow-up.
Outpatient visit rates remained similar, indicating ongoing outpatient care; patients continuously treated for 12 months experienced larger reductions in acute HCRU.

TL;DR (AI Generated)

INTRODUCTION: This study used real-world data to examine changes in healthcare resource utilization (HCRU) among patients with schizophrenia in the 12 months after initiating the combination of olanzapine and samidorphan (OLZ/SAM).

Significant reductions in IP admissions and ED visits were also observed in patients receiving OLZ/SAM treatment for the full 12-month follow-up and were larger than those observed in the full cohort.

CONCLUSION: Among patients with schizophrenia, initiating OLZ/SAM was associated with significant and clinically meaningful reductions in acute HCRU compared with baseline.

Basic summary

Adv Ther. 2026 Nov 13. doi: 10.1007/s12325-026-03831-w. Online ahead of print.

ABSTRACT

METHODS: This retrospective analysis used administrative claims data (October 18, 2020, to December 31, 2023) from the Komodo Healthcare Map. Adults with schizophrenia and continuous enrollment ≥ 12 months before (baseline) and after (follow-up) initiating OLZ/SAM were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of IP days/patient were compared between baseline and follow-up. A subgroup analysis of patients receiving OLZ/SAM treatment for the full 12-month follow-up was conducted.

RESULTS: A total of 1287 patients with schizophrenia initiating OLZ/SAM were included. Mean (SD) age was 38.8 (13.0) years; 53% were male. Patients were persistent for a mean (SD) of 196.6 (144.6) days. Overall, 481 (37.4%) patients received continuous OLZ/SAM treatment for the full 12-month follow-up. Proportions of patients with ≥ 1 all-cause, mental health-related, or schizophrenia-related IP admission or ED visit significantly decreased between baseline and follow-up (range – 13.0% to – 27.3%; all P < 0.001). Average numbers of all-cause, mental health-related, and schizophrenia-related inpatient days per patient decreased significantly (range – 5.2 to – 5.5 days; all P < 0.001). Proportions of patients with ≥ 1 OP visit were similar during baseline and follow-up, indicating that patients continued receiving outpatient care. Significant reductions in IP admissions and ED visits were also observed in patients receiving OLZ/SAM treatment for the full 12-month follow-up and were larger than those observed in the full cohort.

CONCLUSION: Among patients with schizophrenia, initiating OLZ/SAM was associated with significant and clinically meaningful reductions in acute HCRU compared with baseline. Larger reductions in acute care HCRU were observed among patients who received continuous OLZ/SAM treatment throughout the 12-month follow-up period. A video abstract summarizing the study methods, results, and clinical implications is available in the online version of this article. Supplementary file1 (MP4 83203 kb).

PMID:43024145 | DOI:10.1007/s12325-026-03831-w

Document this CPD